Background: Molecular alterations occur frequently in T-ALL and the potential impact of those abnormalities on outcome is still controversial. The current study aimed to test whether NOTCH1 mutations and additional molecular abnormalities would impact T-ALL outcome in a series of 138 T-ALL paediatric cases. Methods: T-ALL subtypes, status of SIL-TAL1 fusion, ectopic expression of TLX3, and mutations in FBXW7, KRAS, PTEN and NOTCH1 were assessed as overall survival (OS) and event-free survival (EFS) prognostic factors. OS and EFS were determined using the Kaplan-Meier method and compared using the log-rank test. Results: The frequencies of mutations were 43.5% for NOTCH1, while FBXW7, KRAS and PTEN exhibited frequencies of 19.1%, 9.5% and 9....
Aberrant activation of the NOTCH1 pathway by inactivating and activating mutations in NOTCH1 or FBXW...
Aberrant activation of the NOTCH1 pathway by inactivating and activating mutations in NOTCH1 or FBXW...
Aberrant activation of the NOTCH1 pathway by inactivating and activating mutations in NOTCH1 or FBXW...
Abstract Background Molecular alterations occur frequently in T-ALL and the potential impact of thos...
Background: Molecular alterations occur frequently in T-ALL and the potential impact of those abnorm...
BackgroundIn children, T-cell acute lymphoblastic leukemia (T-ALL) has inferior prognosis compared w...
We explored the impact of mutations in the NOTCH1, FBW7 and PTEN genes on prognosis and downstream s...
Risk-adjusted treatment stratification in T-cell acute lymphoblastic leukemias (T-ALLs) is currently...
Risk-adjusted treatment stratification in T-cell acute lymphoblastic leukemias (T-ALLs) is currently...
International audiencePURPOSE: Pediatric T-cell lymphoblastic lymphomas (T-LBL) are commonly treated...
International audiencePURPOSE: Pediatric T-cell lymphoblastic lymphomas (T-LBL) are commonly treated...
International audiencePURPOSE: Pediatric T-cell lymphoblastic lymphomas (T-LBL) are commonly treated...
International audiencePURPOSE: Pediatric T-cell lymphoblastic lymphomas (T-LBL) are commonly treated...
Aberrant activation of the NOTCH1 pathway by inactivating and activating mutations in NOTCH1 or FBXW...
Aberrant activation of the NOTCH1 pathway by inactivating and activating mutations in NOTCH1 or FBXW...
Aberrant activation of the NOTCH1 pathway by inactivating and activating mutations in NOTCH1 or FBXW...
Aberrant activation of the NOTCH1 pathway by inactivating and activating mutations in NOTCH1 or FBXW...
Aberrant activation of the NOTCH1 pathway by inactivating and activating mutations in NOTCH1 or FBXW...
Abstract Background Molecular alterations occur frequently in T-ALL and the potential impact of thos...
Background: Molecular alterations occur frequently in T-ALL and the potential impact of those abnorm...
BackgroundIn children, T-cell acute lymphoblastic leukemia (T-ALL) has inferior prognosis compared w...
We explored the impact of mutations in the NOTCH1, FBW7 and PTEN genes on prognosis and downstream s...
Risk-adjusted treatment stratification in T-cell acute lymphoblastic leukemias (T-ALLs) is currently...
Risk-adjusted treatment stratification in T-cell acute lymphoblastic leukemias (T-ALLs) is currently...
International audiencePURPOSE: Pediatric T-cell lymphoblastic lymphomas (T-LBL) are commonly treated...
International audiencePURPOSE: Pediatric T-cell lymphoblastic lymphomas (T-LBL) are commonly treated...
International audiencePURPOSE: Pediatric T-cell lymphoblastic lymphomas (T-LBL) are commonly treated...
International audiencePURPOSE: Pediatric T-cell lymphoblastic lymphomas (T-LBL) are commonly treated...
Aberrant activation of the NOTCH1 pathway by inactivating and activating mutations in NOTCH1 or FBXW...
Aberrant activation of the NOTCH1 pathway by inactivating and activating mutations in NOTCH1 or FBXW...
Aberrant activation of the NOTCH1 pathway by inactivating and activating mutations in NOTCH1 or FBXW...
Aberrant activation of the NOTCH1 pathway by inactivating and activating mutations in NOTCH1 or FBXW...
Aberrant activation of the NOTCH1 pathway by inactivating and activating mutations in NOTCH1 or FBXW...